Results 141 to 150 of about 13,147 (207)

Device-Aided Treatment of Parkinsonism in Cerebrotendinous Xanthomatosis. [PDF]

Mov Disord Clin Pract
Salamon A, Szpisjak L, Klivényi P, Zádori D.   +3 more
europepmc   +1 more source

Foslevodopa+foscarbidopa for advanced Parkinson disease. [PDF]

Aust Prescr
europepmc   +1 more source

Faith, fasting, and well-being: Emirates Neurology Society consensus guidelines on safe Ramadan fasting in Parkinson's disease. [PDF]

Front Neurol
Mittal SO, Krystkowiak P, Ramberg CJ, Sarathchandran P, Hassan A, Iantorno V, Cirasanambati M, Al Aloma M, Maiti T, Al Rukn S.   +9 more
europepmc   +1 more source

Estimation of Dopamine D₁ Receptor Agonist Binding Kinetics Using Time-Resolved Functional Assays: Relation to Agonist-Induced Receptor Internalization by Investigational Antiparkinsonian Therapeutics. [PDF]

ACS Chem Neurosci
Sahlholm K, Svensson P, Malo M, Andersson DR, Betari N.   +4 more
europepmc   +1 more source

Effect of lumbrokinase on a rat model of hyperlipidemia-induced erectile dysfunction. [PDF]

Transl Androl Urol
Li X, Sun Y, Zhang X, Zhang Z, Han Z, Chen Y.   +5 more
europepmc   +1 more source

Outcome of People with Parkinson's Disease Treated with Levodopa-Entacapone-Carbidopa Intestinal Gel Who Failed Previous Subcutaneous Foslevodopa/Foscarbidopa. [PDF]

Brain Sci
Santos García D, Legarda I, González Fernández TM, Rodríguez Sanz A, Morales-Casado MI, Peral A, Caballol N, Álvarez Sauco M, Campos Rodríguez I, Alonso Modino D, López Manzanares L, Olivares Romero J, Blanco Ollero A.   +12 more
europepmc   +1 more source

The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model. [PDF]

Front Endocrinol (Lausanne)
Lingyu Z, Peng F, Wanting Z, Qianqian J, Zhang Z, Bai B, Xue G, Hölscher C.   +7 more
europepmc   +1 more source

Inducing emesis in Australian dogs and cats: agents, adverse effects and antiemetic administration. [PDF]

Aust Vet J
Tsitonakis J, Hall E, Quain A.
europepmc   +1 more source

Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders. [PDF]

CNS Drugs
Detyniecki K, Strzelczyk A, Roebling R, Laloyaux C, Chanteux H, Cloyd JC.   +5 more
europepmc   +1 more source

Sleep disorders in Parkinson's disease: evaluating pharmacological treatments through systematic review and meta-analysis. [PDF]

BMC Neurol
Li J, Zhou R, Deng J, Zhou H, Hu J, Wang X.   +5 more
europepmc   +1 more source